4 results found
Searchresult 1 - 4 of 4. You filter by “Last year” and “Healthcare”.
ACM extends its investigation into the orphan drug CDCA manufactured by Leadiant. The investigation focuses on the pricing of the drug, and on possible abuse of a dominant position.
ACM studies: the insured’s diversity of wishes affects the negotiation balance between health insurers and hospitals
Health insurers must constantly find the right balance between the various wishes of insured. That affects their position in negotiations with hospitals.
ACM: Health insurers are allowed to give health care providers financial support collectively during Coronavirus crisis
Health insurers can make collective arrangements to support health care providers during the Coronavirus (COVID-19) crisis. These arrangements concern continuity contributions and advances on payments to health care providers that are not directly involved in helping Coronavirus patients.